These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 7508727)

  • 1. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy.
    Glaspy JA; Bleecker G; Crawford J; Stoller R; Strauss M
    Eur J Cancer; 1993; 29A Suppl 7():S23-30. PubMed ID: 7508727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
    Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
    Griffiths RI; Barron RL; Gleeson ML; Danese MD; O'Hagan A; Chia VM; Legg JC; Lyman GH
    Pharmacoeconomics; 2012 Feb; 30(2):103-18. PubMed ID: 21967155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor.
    Nichols CR; Fox EP; Roth BJ; Williams SD; Loehrer PJ; Einhorn LH
    J Clin Oncol; 1994 Jun; 12(6):1245-50. PubMed ID: 7515413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial.
    Maher DW; Lieschke GJ; Green M; Bishop J; Stuart-Harris R; Wolf M; Sheridan WP; Kefford RF; Cebon J; Olver I; McKendrick J; Toner G; Bradstock K; Lieschke M; Cruickshank S; Tomita DK; Hoffman EW; Fox RM; Morstyn G
    Ann Intern Med; 1994 Oct; 121(7):492-501. PubMed ID: 7520676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923).
    Tjan-Heijnen VC; Caleo S; Postmus PE; Ardizzoni A; Burghouts JT; Buccholz E; Biesma B; Gorlia T; Crott R; Giaccone G; Debruyne C; Manegold C;
    Ann Oncol; 2003 Feb; 14(2):248-57. PubMed ID: 12562652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: a comparison of collection methods of resource use data.
    Standaert B; Goldstone J; Lu ZJ; Erder MH; Yin JL
    Pharmacoeconomics; 2002; 20(10):665-74. PubMed ID: 12162755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of patients' out-of-pocket costs for granulocyte colony-stimulating factors.
    Tomic K; Long S; Li X; Fu AC; Yu TC; Barron R
    J Oncol Pharm Pract; 2013 Dec; 19(4):328-37. PubMed ID: 23353712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
    N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia.
    Frampton JE; Faulds D
    Pharmacoeconomics; 1996 Jan; 9(1):76-96. PubMed ID: 10161371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health care outcomes case study: Febrile neutropenia.
    Holdsworth MT; Duncan MH
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S15-8. PubMed ID: 8846241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).
    Sebban C; Lefranc A; Perrier L; Moreau P; Espinouse D; Schmidt A; Kammoun L; Ghesquieres H; Ferlay C; Bay JO; Lissandre S; Pérol D; Michallet M; Quittet P
    Eur J Cancer; 2012 Mar; 48(5):713-20. PubMed ID: 22248711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients.
    Mitchell PL; Morland B; Stevens MC; Dick G; Easlea D; Meyer LC; Pinkerton CR
    J Clin Oncol; 1997 Mar; 15(3):1163-70. PubMed ID: 9060560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
    Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
    J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of lenograstim for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer.
    Drummond M; Davies L
    Pharmacoeconomics; 1994; 6 Suppl 2():44-52. PubMed ID: 10155594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy.
    Crawford J; Kreisman H; Garewal H; Jones SE; Shoemaker D; Pupa MR; Armstrong S; Tomita D; Dziem G
    Ann Oncol; 1997 Nov; 8(11):1117-24. PubMed ID: 9426331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma.
    Michon JM; Hartmann O; Bouffet E; Meresse V; Coze C; Rubie H; Bordigoni P; Cattiaux E; Ward N; Bernard JL; Lemerle J; Zucker JM; Philip T
    Eur J Cancer; 1998 Jun; 34(7):1063-9. PubMed ID: 9849455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.
    Gatzemeier U; Ciuleanu T; Dediu M; Ganea-Motan E; Lubenau H; Del Giglio A
    J Thorac Oncol; 2009 Jun; 4(6):736-40. PubMed ID: 19404210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost considerations in therapy with myeloid growth factors.
    Glaspy JA; Jakway J
    Am J Hosp Pharm; 1993 Jul; 50(7 Suppl 3):S19-26. PubMed ID: 7689789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
    J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.